[go: up one dir, main page]

CO5011072A1 - Etanolaminas pirazinil substituidas como agfonistas de los receptores - Google Patents

Etanolaminas pirazinil substituidas como agfonistas de los receptores

Info

Publication number
CO5011072A1
CO5011072A1 CO98071198A CO98071198A CO5011072A1 CO 5011072 A1 CO5011072 A1 CO 5011072A1 CO 98071198 A CO98071198 A CO 98071198A CO 98071198 A CO98071198 A CO 98071198A CO 5011072 A1 CO5011072 A1 CO 5011072A1
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
optionally substituted
heterocycle
hydrogen
Prior art date
Application number
CO98071198A
Other languages
English (en)
Inventor
Thomas Alan Crowell
Charles David Jones
Anthony John Shuker
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5011072A1 publication Critical patent/CO5011072A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

en donde:X1 es -OCH2 -, -SCH2 -, ó un enlace;R1 es un heterociclo de la fórmula:R2 y R3 son independientemente hidrógeno, alquil C1 -C4 , ó aril;R4 es un heterociclo opcionalmente sustituido ó una mitad seleccionada del grupo conformado por:X2 es un enlace, ó un alquileno de 1 a 5 carbonos de cadena recta o ramificada;R5 es hidrógeno ó alquil C1 -C4 ;R6 es hidrógeno ó alquil C1 -C4 ;ó R5 y R6 combinados con el carbono al cual van ligados forman un cicloalquil C3 -C6 ;ó R6 combinado con X2 y el carbono al cual van ligados forman un cicloalquil C3 -C8 ; - 2 -ó R6 se combina con X2 , R4 , y el carbono al cual van ligados, para formar:a condición de que R5 sea hidrógeno;R7 es hidrógeno, hidroxi, ciano, oxo, COn R2 , CONHR2 , alquil C1 -C4 , alcoxi C1 -C4 , haloalquil C1 -C4 , alquil C1 -C4 opcionalmente sustituido, (CH2 )n aril, (CH2 )n heterociclo, (CH2 )n aril opcionalmente sustituido, ó (CH2 )n heterocicloopcionalmente sustituido;R8 es independientemente hidrógeno, halo, ó alquil C1 -C4 ;R9 es halo, CN, OR10 , alquil C1 -C4 , haloalquil C1 -C4 , CO2 R2 , CONR11 R12 , CONH(alquil C1 -C4 ó alcoxi C1 -C4 ), SR2 , CSNHR2 , CSNR11 R12 , SO2 R2 ,SOR2 , NR11 R12 , aril opcionalmente sustituido, heterociclo opcionalmente sustituido, ó alquenil C2 -C4 sustituido con CN, CO2 R2 , ó CONR11 R12 ;R10 es alquil C1 -C4 , haloalquil C1 -C4 , (CH2 )n -cicloalquil C3 -C8 , (CH2 )n aril, (CH2 )n heterociclo, (CH2 )n cicloalquil C3 -C8 opcionalmente sustituido, (CH2 )n aril opcionalmente sustituido, ó (CH2 )n heterociclo opcionalmente sustituido;R11 y R12 son independientemente hidrógeno, alquil C1 -C4 , aril, (CH2 )n aril, ó combinados con el nitrógeno al cual cada uno van ligados forman un anillo morfolinil, piperidinil, pirrolidinil, ó piperazinil;R13 es hidrógeno, halo, aril, ó alquil C1 -C4 ;m es 0 ó 1 ;n es 0, 1, 2, ó 3;ó una sal farmacéuticamente aceptable de éste.
CO98071198A 1997-12-05 1998-12-01 Etanolaminas pirazinil substituidas como agfonistas de los receptores CO5011072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6759997P 1997-12-05 1997-12-05

Publications (1)

Publication Number Publication Date
CO5011072A1 true CO5011072A1 (es) 2001-02-28

Family

ID=22077113

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98071198A CO5011072A1 (es) 1997-12-05 1998-12-01 Etanolaminas pirazinil substituidas como agfonistas de los receptores

Country Status (11)

Country Link
US (2) US6046227A (es)
EP (1) EP0921120A1 (es)
JP (1) JP2001525399A (es)
AR (1) AR017798A1 (es)
AU (1) AU1628199A (es)
CA (1) CA2312987A1 (es)
CO (1) CO5011072A1 (es)
PE (1) PE132699A1 (es)
SV (1) SV1998000142A (es)
WO (1) WO1999029673A1 (es)
ZA (1) ZA9811026B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133409A (en) * 1996-12-19 2000-10-17 Aventis Pharmaceuticals Products Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
AU1572701A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
JP2003514801A (ja) 1999-11-15 2003-04-22 イーライ・リリー・アンド・カンパニー 家畜の生産を改善するためのインダゾリルオキシプロパノールアミン
US6841563B1 (en) * 1999-11-15 2005-01-11 Eli Lilly And Company Aryloxy propanolamines for improving livestock production
BR0015578A (pt) * 1999-11-15 2002-07-09 Lilly Co Eli Arilóxi propanolaminas para melhorar a produção de rebanhos
WO2001036412A1 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
KR100816527B1 (ko) * 2001-09-12 2008-04-10 한국화학연구원 페닐테트라졸 유도체로 치환된 β-아미노알코올 화합물
HRP20050253B1 (hr) * 2002-09-19 2013-11-08 Eli Lilly And Company Diaril eteri kao opioid antagonisti opioidnih receptora
CA2662766C (en) 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
JP5886121B2 (ja) * 2011-07-01 2016-03-16 花王株式会社 メラニン生成抑制剤
RU2014111079A (ru) * 2011-08-25 2015-09-27 Когнишн Терапьютикс, Инк. Композиции и способы для лечения нейродегенеративного заболевания
WO2015025960A1 (ja) * 2013-08-23 2015-02-26 石原産業株式会社 有害生物防除剤
ES2915833T3 (es) 2014-01-31 2022-06-27 Cognition Therapeutics Inc Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
CN105837500A (zh) * 2016-03-31 2016-08-10 常州大学 一种n-(2-(3-(三氟甲基)苯氧基)-4-吡啶基)甲亚胺的合成方法
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
US10865163B2 (en) 2017-12-20 2020-12-15 The University Of Toledo Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE379196B (es) * 1971-06-24 1975-09-29 Sandoz Ag
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA1001161A (en) * 1972-05-05 1976-12-07 Burton K. Wasson 5-(3-substituted amino-2-hydroxypropoxy)1,3-disubstituted pyrazoles and method of preparation
JPS5310974B2 (es) * 1974-06-10 1978-04-18
CH624395A5 (es) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2609645A1 (de) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
US4751246A (en) * 1978-08-30 1988-06-14 Sterling Drug Inc. Compositions and method
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
DE3061334D1 (en) * 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
EP0040000B1 (en) * 1980-05-08 1983-10-12 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
EP0040915B1 (en) * 1980-05-22 1984-03-21 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
DE3264364D1 (en) * 1981-03-06 1985-08-01 Beecham Group Plc Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions
DE3260490D1 (en) * 1981-03-31 1984-09-06 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0063004A1 (en) * 1981-04-09 1982-10-20 Beecham Group Plc Secondary amines, processes for their preparation, and pharmaceutical compositions containing them
EP0068669A1 (en) * 1981-06-20 1983-01-05 Beecham Group Plc Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
EP0070134B1 (en) * 1981-07-11 1985-11-13 Beecham Group Plc Secondary phenyl ethanol amines and their pharmaceutical use
IE54220B1 (en) * 1981-12-23 1989-07-19 Ici Plc Phenol esters
EP0089154A3 (en) * 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
FR2523965B1 (fr) * 1982-03-24 1985-09-27 Bellon Labor Sa Roger (benzimidazolyl-1)-1, n-((hydroxy-4 methoxy-3 phenyl)-2 hydroxy-2 ethyl) amino-3 butane et ses sels a activite b-adrenergique, leurs applications therapeutiques, et procede pour les preparer
EP0095827B1 (en) * 1982-04-08 1985-07-24 Beecham Group Plc N-substituted derivatives of ethanol amine
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0102213A1 (en) 1982-08-21 1984-03-07 Beecham Group Plc Ethanolamine derivatives, pharmaceutical compositions containing them, and processes for preparing them
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
GB8507942D0 (en) * 1985-03-27 1985-05-01 Beecham Group Plc Compounds
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
DE3800096A1 (de) * 1988-01-05 1989-07-13 Bayer Ag Verwendung von benzimidazolderivaten als leistungsfoerderer
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
ATE117980T1 (de) * 1988-06-03 1995-02-15 Lilly Co Eli Serotonin-antagonisten.
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
GB8905336D0 (en) * 1989-03-08 1989-04-19 Ici Plc Chemical compounds
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
EP0499755A1 (fr) * 1991-02-18 1992-08-26 MIDY S.p.A. Nouvelles phényléthanolaminotétralines, procédé pour leur préparation, intermédiaires dans ce procédé et compositions pharmaceutiques les contenant
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9207964D0 (en) * 1992-04-10 1992-05-27 Ici Plc Chemical compounds
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds
WO1994003425A2 (en) * 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Carbostyril derivatives for the treatment of arrhythmia
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5321036A (en) * 1993-02-10 1994-06-14 Bristol-Myers Squibb Company Thiazole and oxazole-based β3 adrenergic receptor agonists
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0627407A1 (fr) * 1993-05-28 1994-12-07 MIDY S.p.A. Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant
CA2164009A1 (en) * 1993-06-14 1994-12-22 Robert L. Dow Secondary amines as antidiabetic and antiobesity agents
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
AU7532294A (en) * 1993-07-31 1995-02-28 Smithkline Beecham Plc 2-benzoheterocyclyloxy or thiopropanolamine derivatives with adreno receptor agonist activity
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5726165A (en) 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
JPH10503507A (ja) * 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ベータ3−アドレナリン受容体アゴニストおよびベータ1およびベータ2−アドレナリン受容体アンタゴニストとして有用なアリールオキシおよびアリールチオプロパノールアミン誘導体、およびその医薬組成物
US5648091A (en) * 1994-08-03 1997-07-15 The Proctor & Gamble Company Stable vitamin A encapsulated
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
FR2801398B1 (fr) * 1999-11-22 2002-01-11 Claude Ricard Procede pour securiser le fonctionnement du capteur electronique associe a un taximetre

Also Published As

Publication number Publication date
EP0921120A1 (en) 1999-06-09
US6046227A (en) 2000-04-04
WO1999029673A1 (en) 1999-06-17
SV1998000142A (es) 1999-10-06
AU1628199A (en) 1999-06-28
PE132699A1 (es) 1999-12-21
US6617347B1 (en) 2003-09-09
CA2312987A1 (en) 1999-06-17
ZA9811026B (en) 2000-06-02
AR017798A1 (es) 2001-10-24
JP2001525399A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
CO5011072A1 (es) Etanolaminas pirazinil substituidas como agfonistas de los receptores
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR016666A1 (es) Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene
AR046615A1 (es) Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos
CO5080767A1 (es) Derivados sulfonamida
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ES2186253T3 (es) Un metodo para controlar la reologia de un fluido acuoso y agente gelificante para dicho control.
CO5261601A1 (es) Indolilquinolinonas utiles como inhibidores de la tirosinoquinasa
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
HN1998000034A (es) Quinoxalinadionas
AR012622A1 (es) Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento
MY128442A (en) Diphenyl ether compounds useful in therapy
AR072045A1 (es) Derivados heterociclicos de urea y metodos para utilizarlos
MX9304151A (es) Nuevas ciclobut-3-en-1,2-dionas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
ES2164881T3 (es) Derivados de 6-carboxamido dihidropirano.
ES2317103T3 (es) Derivados de c-ciclohexilmetilamina sustituidos.
PE20020194A1 (es) 2,3,7,8,9,10,11,12-OCTAHIDROAZEPINO[4,5-b]PIRANO[3,2-e)INDOLES SUSTITUIDOS
ECSP045121A (es) Agonistas del receptor activado por proliferador de peroxisoma